Results 221 to 230 of about 208,237 (324)

Adrenaline vs noradrenaline: Equity, context, and the realities of best practice. [PDF]

Afr J Emerg Med
Hendrikse C.
europepmc   +1 more source

Effects of Nanomolar to Submillimolar Carteolol on Noradrenaline Release in the Absence and Presence of Uptake1 and Uptake2 Blockers in Guinea Pig Pulmonary Arteries.

, 1992
Naoko Matsushita, Misako Kuwahara, Yoshio Goshima, Yoshimi Misu   +3 more
openalex   +2 more sources

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Case report: From metabolic instability to remission: a case of pheochromocytoma presenting as atypical diabetes. [PDF]

Front Endocrinol (Lausanne)
Cao C, Xue P, Yang X, Huang F, Xie Y, Zhou Z.   +5 more
europepmc   +1 more source

A variant of the bovine noradrenaline transporter reveals the importance of the C-terminal region for correct targeting to the membrane and functional expression [PDF]

, 1998
Douglas Burton, G. Andree KIPPENBERGER, Bettina Lingen, Michael Brüss, Heinz Bönisch, Lyndsay Christie   +5 more
openalex   +1 more source

Brief report: Ketamine‐assisted “bridge therapy” for opioid tapering in complex cases

The American Journal on Addictions, EarlyView.
Abstract Background Opioid use disorder (OUD) presents major challenges, especially when combined with chronic pain and psychiatric comorbidities. A 25‐year‐old woman with OUD, chronic pain, and major depressive disorder underwent an 8‐week protocol of intravenous ketamine infusions (0.5 mg/kg weekly) as an adjunct to opioid tapering. Results Methadone
Mariana C. de Oliveira, Cláudia C. de Araujo Palmeira, André B. Negrão, Ziyad A. Hadi, Julia R. Arana, Rita de Cássia Ferreira Duarte, Joice L. P. da Silva, Gustavo K. Matsui, João F. D. Rapozero, Douglas H. Crispim, André Malbergier, João M. Castaldelli‐Maia   +11 more
wiley   +1 more source

The nature of sex differences in catecholamine-induced lipolysis in subcutaneous fat cells. [PDF]

iScience
Massier L, Andersson DP, Viguerie N, Zhong J, Zareifi D, Kerr AG, Langin D, Arner P.   +7 more
europepmc   +1 more source

Effects of noradrenaline and 5-HT reuptake inhibitors on p-chloroamphetamine(PCA)-induced catecholamine release from cultured bovine adrenal chromaffin cells

, 1997
Yuko Shiraishi, Jun Yamada, Yumi Sugimoto, T. Yoshikawa, Kazuvoshi Horieaka   +4 more
openalex   +1 more source

Economic evidence for licensed ready‐to‐administer intravenous products compared with standard vials and ampoules: a systematic review

Anaesthesia, EarlyView.
Summary Introduction Injectable medicines represent a significant proportion of the annual medicines expenditure of the NHS in England, totalling £7 billion ($9.4 billion, €8.0 billion) in 2023. This represents approximately 70% of hospital medicines spending and includes essential treatments delivered at the point of care, such as chemotherapy ...
Suzanne Al‐Rawi, Matthew Greening, Sue Ladds   +2 more
wiley   +1 more source

Structural insights into endogenous agonist selectivity of aminergic receptors from the octopamine β₂ receptor. [PDF]

PNAS Nexus
Hori T, Katsura K, Miyamoto-Kohno S, Uchikubo-Kamo T, Yonemochi M, Shirouzu M.   +5 more
europepmc   +1 more source